ATE309375T1 - Onkostatin- m rezeptor - Google Patents

Onkostatin- m rezeptor

Info

Publication number
ATE309375T1
ATE309375T1 AT95920626T AT95920626T ATE309375T1 AT E309375 T1 ATE309375 T1 AT E309375T1 AT 95920626 T AT95920626 T AT 95920626T AT 95920626 T AT95920626 T AT 95920626T AT E309375 T1 ATE309375 T1 AT E309375T1
Authority
AT
Austria
Prior art keywords
oncostatin
receptor
rbeta
osm
onkostatin
Prior art date
Application number
AT95920626T
Other languages
English (en)
Inventor
Bruce Mosley
David J Cosman
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE309375T1 publication Critical patent/ATE309375T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT95920626T 1994-05-26 1995-05-22 Onkostatin- m rezeptor ATE309375T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24955394A 1994-05-26 1994-05-26
US08/308,881 US5783672A (en) 1994-05-26 1994-09-12 Receptor for oncostatin M
PCT/US1995/006530 WO1995033059A2 (en) 1994-05-26 1995-05-22 Receptor for oncostatin m

Publications (1)

Publication Number Publication Date
ATE309375T1 true ATE309375T1 (de) 2005-11-15

Family

ID=26940161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920626T ATE309375T1 (de) 1994-05-26 1995-05-22 Onkostatin- m rezeptor

Country Status (10)

Country Link
US (7) US5783672A (de)
EP (1) EP0760857B9 (de)
JP (1) JP4392058B2 (de)
AT (1) ATE309375T1 (de)
AU (1) AU694232B2 (de)
CA (1) CA2190371C (de)
DE (1) DE69534593T2 (de)
DK (1) DK0760857T5 (de)
ES (1) ES2249770T3 (de)
WO (1) WO1995033059A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
GB9419021D0 (en) * 1994-09-21 1994-11-09 Applied Research Systems Therapeutic protein
US5674995A (en) * 1995-06-07 1997-10-07 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
KR19990022359A (ko) * 1995-06-07 1999-03-25 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 시토킨 시그날 트랜스듀서 ｇｐ130 ｍＲＮＡ에 특이적인 올리고뉴클레오티드
US5747470A (en) * 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
AU723057B2 (en) * 1995-11-07 2000-08-17 Kaneka Corporation Autoantigen
CA2272050A1 (en) * 1996-11-20 1998-05-28 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
DE69834027D1 (de) * 1997-01-14 2006-05-18 Human Genome Sciences Inc Tumor-nekrose-faktor rezeptor 5
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US6271343B1 (en) * 1997-05-01 2001-08-07 Zymogenetics, Inc. Mammalian cytokine-like receptor 5
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
PT1105485E (pt) * 1998-08-21 2006-11-30 Immunex Corp Dna e polipeptídeos de il-1 epsilon humana
US6803451B2 (en) 1998-09-23 2004-10-12 Zymogenetics, Inc. Cytokine receptor zalpha11 polypeptides
US6576744B1 (en) 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
EP2325316B8 (de) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Neues Hämopoietin Receptorprotein, NR10
DE60025241T2 (de) 1999-09-27 2007-01-11 Chugai Seiyaku K.K. HäMOPOIETINREZEPTOR-PROTEIN, NR12
WO2001077171A2 (en) * 2000-04-05 2001-10-18 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
ATE382636T1 (de) * 2000-04-21 2008-01-15 Conaris Res Inst Ag Fusionsproteine, die zwei lösliche gp130 moleküle enthalten
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
US9738700B2 (en) 2002-01-18 2017-08-22 Zymogenetics Inc. ZCYTOR17 heterodimeric cytokine receptor
EP1576112B1 (de) * 2002-01-18 2012-02-29 ZymoGenetics, Inc. Multimere des cytokinrezeptors zcytor17
US7261861B2 (en) 2003-04-24 2007-08-28 Haemoscope Corporation Hemostasis analyzer and method
EP1491554A1 (de) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGlierte lösliche gp130-Dimeren geignet als Medikament
EP1765868B1 (de) * 2004-06-07 2016-04-20 MacroGenics, Inc. Antikörper gegen den transferrinrezeptor
EP1630232B1 (de) * 2004-08-27 2008-07-02 CONARIS research institute AG Optimierte Nukleotidsequenzen die für sgp130 kodieren
JP5328156B2 (ja) * 2005-02-03 2013-10-30 マクロジェニックス ウエスト， インコーポレイテッド オンコスタチンｍレセプターに対する抗体
US20090203639A1 (en) * 2005-04-15 2009-08-13 Oncomethylome Sciences, Inc. Methylation Markers for Diagnoses and Treatment of Cancers
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
KR101446989B1 (ko) 2005-05-06 2014-10-15 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
CA2636288C (en) 2006-01-10 2015-02-24 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
US7932055B2 (en) 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
ATE480568T1 (de) 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
US8309688B2 (en) * 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
WO2012069433A2 (en) 2010-11-23 2012-05-31 Glaxo Group Limited Antigen binding proteins
JP6214010B2 (ja) * 2012-05-11 2017-10-18 公立大学法人和歌山県立医科大学 抗オンコスタチンｍ受容体ベータ抗体
CN110511279B (zh) 2013-05-30 2024-03-29 基尼克萨制药有限公司 制瘤素m受体抗原结合蛋白
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US20170327573A1 (en) 2014-09-24 2017-11-16 Universitá Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
MX2017007067A (es) 2014-12-01 2018-04-30 Ferring Bv Administracion de un inhibidor selectivo de la trans-señalizacion de il-6.
MD3227325T2 (ro) 2014-12-01 2024-09-30 Ferring Bv Compoziții de inhibitor selectiv trans-semnalizare de IL-6
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120535A (en) * 1986-11-26 1992-06-09 Oncogen Oncostatin M and novel compositions having anti-neoplastic activity
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
US5106731A (en) * 1988-10-21 1992-04-21 The United States Of America As Represented By The Department Of Health And Human Services Kaposi's sarcoma endothelial cells and growth factor
IL112768A (en) * 1989-04-10 1998-06-15 Oncogen Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
JP2898064B2 (ja) * 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
ES2120958T3 (es) * 1989-12-08 1998-11-16 Bristol Myers Squibb Co Nuevas proteinas con actividad de oncostatina m y procedimiento para su preparacion.
ZA912137B (en) * 1990-03-29 1992-11-25 Oncogen Monocional antibodies that inhibit growth of kaposi's sarcoma
CA2097291A1 (en) * 1990-12-13 1992-06-14 David P. Gearing Leukemia inhibitory factor receptors
US5470824A (en) * 1991-05-31 1995-11-28 The Regents Of The University Of California Method to treat Kaposi's sarcoma
KR930703715A (ko) * 1991-11-12 1993-11-30 다쯔타 도키오 접어진 스트립 선로형 유전체 공진기 및 그것을 사용한 적층형 유전체 필터
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5284744A (en) * 1992-08-27 1994-02-08 Eastman Kodak Company Non-ultraviolet-absorbing peptizer for silver halide emulsions
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M

Also Published As

Publication number Publication date
CA2190371C (en) 2010-08-31
EP0760857B1 (de) 2005-11-09
WO1995033059A3 (en) 1996-01-04
DE69534593T2 (de) 2006-08-10
DK0760857T3 (da) 2006-01-30
EP0760857B9 (de) 2006-09-06
EP0760857A1 (de) 1997-03-12
US6524817B1 (en) 2003-02-25
AU2601695A (en) 1995-12-21
AU694232B2 (en) 1998-07-16
US20030109003A1 (en) 2003-06-12
DE69534593D1 (de) 2005-12-15
DK0760857T5 (da) 2006-10-30
US5783672A (en) 1998-07-21
US20050260197A1 (en) 2005-11-24
US6010886A (en) 2000-01-04
ES2249770T3 (es) 2006-04-01
JP4392058B2 (ja) 2009-12-24
JPH10501131A (ja) 1998-02-03
US5925740A (en) 1999-07-20
WO1995033059A2 (en) 1995-12-07
CA2190371A1 (en) 1995-12-07
US5891997A (en) 1999-04-06

Similar Documents

Publication Publication Date Title
ATE309375T1 (de) Onkostatin- m rezeptor
ATE187982T1 (de) Cytokine antagoniste
ATE136906T1 (de) Antikörperantagonisten gegen humanes interleukin- 4
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
DK0403156T3 (da) Forbedrede monoklonale antistoffer mod den humane alfa/beta-T-cellereceptor samt fremstilling og anvendelse deraf
EA200000565A1 (ru) Цитокин-подобный полипептид-10 млекопитающих
DE69323768D1 (de) Pyrrolopyrimidine als crf antagonisten
DE69738841D1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
DE69434213D1 (de) Verwendung von Zusatzstoffen in Treibstoffzusammensetzungen
DE69514342D1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
NO995182D0 (no) Pattedyrcytokinlignende faktor 7
DE69032357D1 (de) Rekombinanter Interleukin-2-Rezeptor
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
ATE132162T1 (de) Humane gammainterferonantagonisten
PT734380E (pt) 4-benzoilisoxazois e sua utilizacao como herbicidas
DE69433914D1 (de) Die Verwendung von Schmiermittel für Zweitaktmotor mit Direkteinspritzung
DE69230659D1 (de) Polypeptide, die an die schweren Ketten von IL-2-Rezeptoren binden können
RU94026276A (ru) Рецепторы интерлейкина-12 и антител
SE8702724D0 (sv) Proteins and protein compositions and their use
NO912072L (no) Rekombinante proteiner med adipsin- og komplement-d-aktiviteter.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0760857

Country of ref document: EP

REN Ceased due to non-payment of the annual fee